Red Face Test

Quote

anonymous

Guest
Paul and Tom can't pass the red face test. I am talking about the embarrassment of CLL market share bonus and performance rating. No where else in this industry would a 20% Medicare diagnosis sample from 3rd and 4th level oncologists be acceptable as a method of performance measurement and IC. From the 20% sample of low prescriber ranking oncologists, it is not measuring how we do in garnering new patients in CLL vs. the competition. It measures the rate of how well we cannibalize the total usage of Bendamustine in favor of a CLL diagnosis. Makes zero sense! But Paul won't hear of any objection and Tom's million dollar investment in the crappy database rules. The emperor has no clothes! We would be better off deciding IC and performance by playing roulette.
 






anonymous said:
Paul and Tom can't pass the red face test. I am talking about the embarrassment of CLL market share bonus and performance rating. No where else in this industry would a 20% Medicare diagnosis sample from 3rd and 4th level oncologists be acceptable as a method of performance measurement and IC. From the 20% sample of low prescriber ranking oncologists, it is not measuring how we do in garnering new patients in CLL vs. the competition. It measures the rate of how well we cannibalize the total usage of Bendamustine in favor of a CLL diagnosis. Makes zero sense! But Paul won't hear of any objection and Tom's million dollar investment in the crappy database rules. The emperor has no clothes! We would be better off deciding IC and performance by playing roulette.
Click to expand...

Leadership is insecure and unwilling to take on levels above themselves to secure real sales goals. We are all victims on the dysfunction with this IC plan.
 






The only reason benda is still being used is because it make MDs $$ in combo..the non chemo trend request by patient is growing. Plus the data show Benda is just as toxic as regular chemo.. But your label will never be updated. Lower your price and pray it is use in more relevant combos.
 












Who cares anyways? All the good people have left and considering this operation as an oncology company is a joke.
I understand that the patent victory will not stop the Eagle liquid launch, so the bidding wars will continue with all major marketing efforts.
 


















Talk about red faced after today's conference call - no, we are not for sale just women's health. Yes, we are for sale like women's health. We are making deals. No, we are not investing in oncology.

Paul, this is embarrassing!
 






We are definitely on the market and will be sold off at the first viable offer. Teva needs fast cash and they need it right now. The CFO is leaving. The mice are jumping off the sinking ship.
 












anonymous said:
Talk about red faced after today's conference call - no, we are not for sale just women's health. Yes, we are for sale like women's health. We are making deals. No, we are not investing in oncology.

Paul, this is embarrassing!
Click to expand...

I cannot help but think that Paul is either the eternal optimist or a blind man. After the POA I have to seriously think about who would partner with us for a co-promote? It is clear to the rest of the free world that we do not invest in oncology so why do business with us?

Paul, stop with the 'pie-in-the-sky' approach. It is quite old already and you look silly.
 






anonymous said:
I cannot help but think that Paul is either the eternal optimist or a blind man. After the POA I have to seriously think about who would partner with us for a co-promote? It is clear to the rest of the free world that we do not invest in oncology so why do business with us?

Paul, stop with the 'pie-in-the-sky' approach. It is quite old already and you look silly.
Click to expand...

Paul is similar to an actor. Being the puppet actor for his upper levels has got him to this point in his career. He does not care about lying to the field. He continues to prosper as a result. When this division folds, they will plug his ass kissing face into another VP role.
 
























Top Bottom
Back
Quote